Home › Major Depressive Disorder › Maryland
Major Depressive Disorder clinical trials in Maryland
20 studies for Major Depressive Disorder are looking for participants at sites in Maryland.
Cities in Maryland
Characterization and Treatment of Adolescent Depression
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational studyHealthy volunteers welcome
Ages 11 to 25 · All sexes · Updated Sep 28, 2026 · NCT03388606A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)
- Delricht Research - Rockville, Rockville
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07621237A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
- Johns Hopkins University, Baltimore
RecruitingPhase 3
Ages 12 to 17 · All sexes · Updated Sep 25, 2026 · NCT07227454A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
- Sunstone Medical, PC, Rockville
RecruitingPhase 3
Ages 18 to 85 · All sexes · Updated Sep 25, 2026 · NCT06793397Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 1Healthy volunteers welcome
Ages 18 to 65 · All sexes · Updated Sep 22, 2026 · NCT03065335Study of Neuro-Cognitive Correlates of Pediatric Anxiety Disorders
- National Institutes of Health Clinical Center, Bethesda
- University of Maryland, College Park, College Park
RecruitingPhase 2Healthy volunteers welcome
Ages 8 to 65 · All sexes · Updated Sep 22, 2026 · NCT00018057Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 2
Ages 18 to 70 · All sexes · Updated Sep 14, 2026 · NCT06511908Defining Neurobiological Links Between Substance Use and Mental Illness
- National Institute on Drug Abuse, Baltimore
RecruitingHealthy volunteers welcome
Ages 18 to 60 · All sexes · Updated Sep 11, 2026 · NCT05538910Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 1
Ages 18 to 70 · All sexes · Updated Sep 10, 2026 · NCT03973268Neurobiology of Suicide
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 2Healthy volunteers welcome
Ages 18 to 70 · All sexes · Updated Sep 9, 2026 · NCT02543983A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
- Pharmasite Research Inc., Baltimore
RecruitingPhase 3
Ages 18 to 74 · All sexes · Updated Sep 8, 2026 · NCT07076407A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder
- Pharmasite Research, Inc., Baltimore
RecruitingPhase 3
Ages 18 to 74 · All sexes · Updated Aug 28, 2026 · NCT07573176A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression
- Draig Clinical Site, Gaithersburg
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Aug 26, 2026 · NCT07300969Natural History of Depression, Bipolar Disorder and Suicide Risk
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational study
Ages 18 to 120 · All sexes · Updated Aug 14, 2026 · NCT06462196NIMH Rhythms and Blues Study: A Prospective Natural History Study of Motor Activity, Mood States, and Bipolar Disorder
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational studyHealthy volunteers welcome
Ages 8 to 70 · All sexes · Updated Aug 13, 2026 · NCT05669703A Study of Brenipatide in Adult Participants With Major Depressive Disorder
- Pharmasite Research, Inc., Baltimore
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Aug 6, 2026 · NCT07412756A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
- Continental Clinical Solutions, Towson
RecruitingPhase 2
Ages 18 to 64 · All sexes · Updated Jul 27, 2026 · NCT07115329Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Gaithersburg
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Jul 24, 2026 · NCT06966401Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
- Clinical Research Site, Pikesville
RecruitingPhase 3
Ages 18 to 65 · All sexes · Updated Jul 24, 2026 · NCT07484217A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
- Sheppard Pratt, Baltimore
- Sunstone Medical, PC, Rockville
RecruitingPhase 2
Ages 18 to 65 · All sexes · Updated May 11, 2026 · NCT06524830From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.